Every 8-K that Estrella Immunopharma, Inc. Warrant (ESLAW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ESLAW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ESLAW filings page.
Estrella Immunopharma, Inc. (ESLA) reported receiving a notice from Nasdaq on September 1, 2026 that it no longer meets the Nasdaq Capital Market’s minimum $35,000,000 market value of listed securities requirement, after its MVLS stayed below that level for 30 consecutive business days.
Nasdaq also noted that the company does not meet the alternative standards for stockholders’ equity of at least $2,500,000 or net income of at least $500,000. ESLA has 180 calendar days, until March 1, 2027, to regain compliance by having MVLS at or above $35,000,000 for at least ten consecutive business days. Its common stock and warrants continue to trade on the Nasdaq Capital Market during this compliance period.
Estrella Immunopharma, Inc. (ESLA) reported that on August 17, 2026 it received a Nasdaq notice that its common stock no longer meets the $1.00 minimum bid price requirement, after trading below $1.00 for 30 consecutive business days from July 6 through August 14, 2026. The stock continues to trade on the Nasdaq Capital Market under “ESLA” while the company has 180 calendar days, until February 16, 2027, to regain compliance by having a closing bid of at least $1.00 for at least ten consecutive business days, or longer at Nasdaq’s discretion. Estrella may use tools such as a reverse stock split, which would need to be completed at least ten business days before the compliance deadline, and could receive an additional 180-day period if it meets other Nasdaq listing standards. The company plans to monitor its share price and evaluate options, but states there is no assurance it will regain or maintain compliance.
Estrella Immunopharma, Inc. reported the results of its Combined 2025/2026 Annual Meeting of Stockholders held virtually on June 29, 2026. Stockholders voted on one proposal: ratification of the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
There were 43,034,228 shares of common stock outstanding and entitled to vote as of May 20, 2026, the record date. Holders of 30,351,608 shares were present or represented by proxy, representing approximately 70.5% of the eligible shares and establishing a quorum. Stockholders ratified the appointment of Macias Gini & O’Connell LLP with 30,351,203 votes for, 400 votes against, 5 abstentions and no broker non-votes.